Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 4 art units • 5 examiners • 0 of 7 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Omeros Corporation currently manages 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 5 distinct examiners and 4 distinct art units. This distribution shows that the company's biotech filings are spread across several different technical groups and individual reviewers at the patent office. The presence of 4 art units for 7 actions suggests that while there is some concentration, the portfolio still spans multiple administrative divisions.
KIFLE, BRUCK is the busiest examiner for the company, overseeing 2 pending office actions. This accounts for a portion of the 7 total pending actions currently active. The remaining actions are split among other distinct examiners, meaning most examiners are handling only a single matter each. Because there are 5 examiners and 4 art units, it is likely that some examiners share the same art unit, providing a small degree of administrative overlap despite the variety of personnel.
The concentration of 2 pending actions under KIFLE, BRUCK makes him the primary point of contact for the company's current Biotechnology & Pharmaceuticals prosecution. However, with 5 distinct examiners in total, the majority of the 7 pending actions are still being reviewed independently. The use of 4 distinct art units indicates that the technical subject matter is diverse enough to require oversight from various supervisory groups.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 4 (57%) |
| Multi-statute (no §101) | 2 (29%) |
| No statute on record | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIFLE, BRUCK | 2 | 79.2% | +15.9% |
| SKELDING, ZACHARY S | 2 | 59.7% | +41.2% |
| KIM, YUNSOO | 1 | 65.9% | +34.3% |
| CANELLA, KAREN A | 1 | 62.2% | +32.8% |
| LI, RUIXIANG | 1 | 59.5% | +18.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18656093 | Methods for Inhibiting Fibrosis in a Subject in Need Thereof | SKELDING, ZACHARY S | — |
| 17938421 | TARGETED CATALYTIC COMPLEMENT-ACTIVATING MOLECULES AND METHODS OF USE THEREOF | LI, RUIXIANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18176155 | HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS | KIM, YUNSOO | 121d overdue |
| 18168192 | COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION | SKELDING, ZACHARY S | 33d |
| 18776612 | MASP-2 INHIBITORS AND METHODS OF USE | KIFLE, BRUCK | — |
| 18777239 | MASP-2 INHIBITORS AND METHODS OF USE | KIFLE, BRUCK | — |
| 18656093 | Methods for Inhibiting Fibrosis in a Subject in Need Thereof | SKELDING, ZACHARY S | — |
| 18063018 | THERAPEUTIC ANTIBODIES THAT BIND TO THE SERINE PROTEASE DOMAIN OF MASP-2 AND USES THEREOF | CANELLA, KAREN A | — |
| 17938421 | TARGETED CATALYTIC COMPLEMENT-ACTIVATING MOLECULES AND METHODS OF USE THEREOF | LI, RUIXIANG | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1644 | 1 |
| 1643 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18776612 | MASP-2 INHIBITORS AND METHODS OF USE | KIFLE, BRUCK | — | §112 | Final Rejection | — | Pending | Jul 18, 2024 |
| 18777239 | MASP-2 INHIBITORS AND METHODS OF USE | KIFLE, BRUCK | — | §112 | Final Rejection | — | Pending | Jul 18, 2024 |
| 18656093 | Methods for Inhibiting Fibrosis in a Subject in Need Thereof | SKELDING, ZACHARY S | — | §102§103 | Non-Final OA | — | Pending | May 06, 2024 |
| 18176155 | HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS | KIM, YUNSOO | 1641 | §112 | Final Rejection | 121d overdue | Pending | Feb 28, 2023 |
| 18168192 | COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION | SKELDING, ZACHARY S | 1644 | Other | Non-Final OA | 33d | Pending | Feb 13, 2023 |
| 18063018 | THERAPEUTIC ANTIBODIES THAT BIND TO THE SERINE PROTEASE DOMAIN OF MASP-2 AND USES THEREOF | CANELLA, KAREN A | 1643 | §112Other | Non-Final OA | — | Pending | Dec 07, 2022 |
| 17938421 | TARGETED CATALYTIC COMPLEMENT-ACTIVATING MOLECULES AND METHODS OF USE THEREOF | LI, RUIXIANG | 1674 | §102§112 | Non-Final OA | — | Pending | Oct 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial